Biography
Marco Infante obtained his M.D. degree with honors at Sapienza University of Rome in 2014. In 2019, he received the Board Certification in Endocrinology and Metabolic Disorders, with honors, at the University of Rome Tor Vergata. In 2023, he obtained the Ph.D. degree in Systems and Experimental Medicine (European Ph.D. Label) at the University of Rome Tor Vergata, with the final evaluation of “Excellent quality, with honors”. Starting from January 2019, Dr. Infante has been serving as a Research Scholar at the Diabetes Research Institute (DRI) of the University of Miami Miller School of Medicine (Miami, FL, USA), where he has been involved in clinical research in the field of type 1 diabetes mellitus, pancreatic islet transplantation, diabetes technology and immunotherapies for treatment of type 1 diabetes. Starting from 2020, he has been holding the position of Adjunct Professor of Endocrinology at UniCamillus – Saint Camillus International University of Health Sciences – Faculty of Medicine and Surgery (Rome, Italy). In 2020, he has been appointed Distinguished Supervisor for the international Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) of the Universal Scientific Education and Research Network (USERN). In 2021, Dr. Infante received the designation as Fellow of the American College of Nutrition (FACN) by virtue of his research activity in the field of “Immunomodulatory Nutrition”. In 2022, he has been appointed Adjunct Professor of Applied Nutrition in Internal Medicine at UniCamillus – Saint Camillus International University of Health Sciences (Rome, Italy). In recognition of his significant scientific contributions to the field of diabetes mellitus, in August 2023 Dr. Marco Infante has been inducted, as a Full Member, into the Sigma Xi Scientific Research Honor Society, the world’s largest interdisciplinary scientific honor society founded in 1886 at Cornell University (Ithaca, NY, USA). Moreover, he is currently serving as Associate Editor and Academic Editor of the international peer-reviewed journals “Frontiers in Clinical Diabetes and Healthcare” and “Journal of Diabetes Research” (Wiley publisher), respectively.
In May 2024, the USCIS (U.S. Citizenship and Immigration Services) granted Dr. Marco Infante the U.S. Extraordinary Ability O1 Visa for Extraordinary Ability in the Sciences.
UniCamillus
Marco Infante serves as Adjunct Professor of Endocrinology and Applied Nutrition in Internal Medicine at UniCamillus – Saint Camillus International University of Health Sciences, Faculty of Medicine and Surgery (Rome, Italy).
DRIF
Dr. Infante serves as a Research Scholar at the Diabetes Research Institute (DRI) of the University of Miami Miller School of Medicine (Miami, FL, USA). Dr. Infante is also a member of several national and international scientific organizations and societies, including the American Diabetes Association (ADA), the American Nutrition
Association (ANA), the International Pancreas and Islet Transplant Association (IPITA), the European
Atherosclerosis Society (EAS), the Italian Society of Endocrinology (SIE), the Italian Society of Diabetology (SID), and the Diabetes Research Institute Federation (DRIF, Rome Chapter, University of Rome Tor Vergata), a global alliance of researchers who are focused on the cure research for type 1 diabetes mellitus.
ARTICLES
BOOKS
Ruoli editoriali
Dr. Infante serves as Academic Editor of the international peer-reviewed scientific journal Journal of Diabetes Research (Wiley publisher) and as Associate Editor of the international peer-reviewed scientific journal Frontiers in Clinical Diabetes and Healthcare. Dr. Infante also serves as Managing Editor of CellR4, an international, peer-reviewed, open access and multidisciplinary scientific journal covering various aspects of regenerative medicine, from basic research to translational medicine and clinical trials.
Monographies
“Evolving Concepts in Insulin Resistance” – Academic Editor: Marco Infante (published by IntechOpen in December 2022). This book presents a comprehensive overview of the pathophysiology and clinical consequences of insulin resistance in different settings, describing novel diagnostic biomarkers and molecular targets of this condition.